|1.||Swinnen, Johannes V: 3 articles (01/2014 - 09/2007)|
|2.||Smans, Karine: 2 articles (01/2014 - 10/2010)|
|3.||Daniëls, Veerle W: 2 articles (01/2014 - 10/2010)|
|4.||Verhoeven, Guido: 2 articles (10/2010 - 09/2007)|
|5.||Timmermans, Leen: 2 articles (10/2010 - 09/2007)|
|6.||Brusselmans, Koen: 2 articles (10/2010 - 09/2007)|
|7.||Scheys, Katryn: 2 articles (10/2010 - 09/2007)|
|8.||Bähre, Heike: 1 article (11/2014)|
|9.||Sandouk, Aline: 1 article (11/2014)|
|10.||Sparwasser, Tim: 1 article (11/2014)|
09/01/2007 - "Here, using the potent ACC inhibitor soraphen A, a macrocyclic polyketide from myxobacteria, we show that ACC activity in cancer cells is essential for proliferation and survival. "
01/01/2014 - "Consequently, cancer cells grown in lipid-reduced conditions became more dependent on de novo lipid synthesis pathways and were more sensitive to inhibitors of lipogenic pathways, like Soraphen A and Simvastatin. "
10/15/2010 - "Reversal of the lipogenic switch in cancer cells by treatment with the lipogenesis inhibitor soraphen A or by targeting lipogenic enzymes with small interfering RNA leads to a marked decrease in saturated and mono-unsaturated phospholipid species and increases the relative degree of polyunsaturation. "
|2.||Prostatic Neoplasms (Prostate Cancer)
|3.||Autoimmune Diseases (Autoimmune Disease)
|1.||Small Interfering RNA (siRNA)